SGLT-2 diabetes drugs linked to lower risk of autoimmune diseases
Replication in other populations and settings needed to confirm and extend these observations, say researchers Sodium-glucose cotransporter-2 (SGLT-2) inhibitors used to treat type 2 diabetes are associated with an 11% lower risk of autoimmune rheumatic diseases, such as rheumatoid arthritis and lupus, compared with another group of diabetes drugs called ...

